fullscreen

eFinder

eFinder

Home › Financial Advice › Article

Cramer's lightning round: 'I like Vistra'

Cnbc · · 190 words · By Alexa LoMonaco
Financial Advice Stock Market Analysis
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Financial Advice

Recursion Pharmaceuticals: "I think that company better come up with something soon because right now all it is coming up with is losses, and that is not the way it should be." Fastly: "That thing came back from the abyss.

Claims checked 3
Techniques found 2
Topics 2

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

1 source compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Recursion Pharmaceuticals: "I think that company better come up with something soon because right now all it is coming up with is losses, and that is not the way it should be." Fastly: "That thing came back from the abyss.

Why it matters

I have to tell you, I still like Cloudflare more, but I hand it to those guys.

Common ground

I also like Akamai, but Fastly's in the game, and it's not easy to be in that game." NextEra Energy: "I don't like Nextera.

Perspective signals

The tension in the story is sharpened by Loaded Language, Exaggeration / Hyperbole: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/08/12/cramers-lightning-round-i-like-vistra.html

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.
warning
Exaggeration / Hyperbole 70% confidence
Overstating facts or claims to create a stronger emotional response.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 3 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 1
verified Verified By Reference 1
verified Verified 1
check_circle
Claim 1: “Fastly's in the game”
CORROBORATED
Multiple independent sources (Fastly's own site, ForesightIQ, and The Motley Fool) confirm that Fastly is an active participant in the CDN and edge cloud services market.
travel_explore
web search NEUTRAL — What products does Fastly offer? Fastly offers a suite of products across performance and security, including CDN for content delivery, WAF for application protection, DDoS mitigation, bot management,…
https://www.fastly.com/?utm_adgroupid=116758579605&utm_chann…
travel_explore
web search NEUTRAL — Fastly Product and Pricing Intelligence. Fastly (fastly.com) offers a programmable edge cloud platform designed to build, secure, and deliver sites and applications instantly. Their core offerings inc…
https://www.foresightiq.co/competitive-landscape/fastly
travel_explore
web search NEUTRAL — Fastly's competitive advantage. Fastly specializes in edge computing, which brings data from a central server in the cloud to a data center much closer to a user's location. This allows for speed, sec…
https://www.fool.com/investing/2021/04/23/is-fastly-stock-a-…
verified
Claim 2: “This President seems to be inclined to be able to give the Navy a lot of money”
VERIFIED BY REFERENCE
The claim describes a subjective 'inclination' or internal state of the President regarding funding. While Wikipedia confirms the President is the commander-in-chief, the provided evidence contains no specific budget proposals, statements, or funding data to verify whether the current President is specifically 'inclined' to give the Navy 'a lot of money'.
menu_book
wikipedia NEUTRAL — The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term via the Electoral College. Under the U.S. Constitution, the …
https://en.wikipedia.org/wiki/List_of_presidents_of_the_Unit…
menu_book
wikipedia NEUTRAL — The president of the United States (POTUS) is the head of state and head of government of the United States. The president directs the executive branch of the federal government and is the commander-i…
https://en.wikipedia.org/wiki/President_of_the_United_States
menu_book
wikipedia NEUTRAL — The vice president of the United States (VPOTUS, VP, or informally veep) is the second-highest office in the executive branch of the U.S. federal government, after the president of the United States, …
https://en.wikipedia.org/wiki/Vice_President_of_the_United_S…
+ 3 more evidence sources
verified
Claim 3: “Recursion Pharmaceuticals... right now all it is coming up with is losses”
VERIFIED
MarketWatch explicitly reports that Recursion Pharmaceuticals reported a fourth-quarter loss of $178.9 million, which was wider than analysts expected, confirming the claim that the company is reporting losses.
travel_explore
web search NEUTRAL — Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://finance.yahoo.com/quote/RXRX/
travel_explore
web search NEUTRAL — Recursion Pharma, currently carrying a Zacks Rank #3 (Hold), has a first-mover advantage in AI-driven drug discovery, which positions it as a leader in the space, with a strong pipeline focused on Pre…
https://www.nasdaq.com/articles/recursion-pharma-down-37-mon…
travel_explore
web search NEUTRAL — Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected. The clinical-stage biotechnology company said it had a qu…
https://www.marketwatch.com/story/recursion-pharma-shares-dr…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.